All In Biotech

Drug Trial Radar · NCT04041648

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of L606 for Inhalation in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Nov 9, 2018

Primary completion

Sep 20, 2019

Study completion May 12, 2020

Sponsor

Lead sponsor
Pharmosa Biopharm Inc.Industry
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Aug 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • L606 (Liposomal Treprostinil) Inhalation Solution 51ugDrug

    Single ascending dose

  • L606 Inhalation SystemDevice

    Single ascending dose

  • Placebo SolutionOther

    Single ascending dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of treatment-emergent adverse events for L606 and placebo, including abnormal laboratory eventsTime frame: From Pre-dose to Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.